Recent investigations have demonstrated that the therapeutic efficacy of ICI is superior in patients with substantial intratumoral CD8 + T cell infiltration, tumor mutational load, and the expression of PD-L1 by tumor cells [81–84]. This evidence concerns the gene CD274 and neoplasm.